Misplaced Pages

Mazaticol

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is the current revision of this page, as edited by Boghog (talk | contribs) at 13:36, 26 December 2023 (consistent citation formatting). The present address (URL) is a permanent link to this version.

Revision as of 13:36, 26 December 2023 by Boghog (talk | contribs) (consistent citation formatting)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Chemical compound Pharmaceutical compound
Mazaticol
Clinical data
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: uncontrolled
Identifiers
IUPAC name
  • non-3-yl hydroxy(di-2-thienyl)acetate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H27NO3S2
Molar mass405.57 g·mol
3D model (JSmol)
SMILES
  • CC1(CC2C(C1N2C)OC(=O)C(c3cccs3)(c4cccs4)O)C
InChI
  • InChI=1S/C21H27NO3S2/c1-20(2)9-8-14-12-15(13-16(20)22(14)3)25-19(23)21(24,17-6-4-10-26-17)18-7-5-11-27-18/h4-7,10-11,14-16,24H,8-9,12-13H2,1-3H3/t14-,15-,16-/m1/s1
  • Key:AMHPTVWBZSYFSS-BZUAXINKSA-N
  (verify)

Mazaticol (Pentona) is an anticholinergic used as an antiparkinsonian agent in Japan.

The compound was known as PG-501 is first mentioned in Japanese studies in the early 1970s, noting "PG-501 was found to have pronounced anti-acetylcholine, anti-tremorine-induced tremor, anti-physostigmine-induced death, anti-haloperidol-induced parkinsonism and anti EEG arousal activities."

References

  1. Nose T, Kojima M, Ishida R, Shintomi K, Kowa Y (July 1971). "[Pharmacological properties of 6,6,9-trimethyl-9-azabicyclo (3,3,1)non-3 beta-yl-alpha, alpha-di(2-thienyl) glycolate hydrochloride monohydrate (PG-501), a new anti-parkinsonian agent]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 67 (4): 387–405. doi:10.1254/fpj.67.387. PMID 5000167.
  2. Kosaka K (1971). "パ ー キ ン ソ ン病 に対 す るPG-501の 使 用 経 験/The Beneficial Effect of PG-501 on Parkinsonism". Rinsho Yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 2 (3): 230–235. doi:10.3999/jscpt.2.230. Retrieved December 18, 2023.

External links

Antiparkinson agents (N04)
Dopaminergics
DA precursors
DA receptor agonists
MAO-B inhibitors
COMT inhibitors
AAAD inhibitors
Anticholinergics
Others
Muscarinic acetylcholine receptor modulators
mAChRsTooltip Muscarinic acetylcholine receptors
Agonists
Antagonists
Precursors
(and prodrugs)
See also
Receptor/signaling modulators
Nicotinic acetylcholine receptor modulators
Acetylcholine metabolism/transport modulators
Stub icon

This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it.

Categories: